Navigation Links
Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
Date:2/12/2008

Recent Product Introductions Drive 49% Revenue Growth and Gross Margin of

66%

WESTFORD, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced record revenues and net income for the quarter and year ended December 31, 2007.

Fourth Quarter 2007 Financial Results

Revenues increased 49% to $36.6 million in the fourth quarter of 2007 from $24.6 million for the fourth quarter of 2006. Gross profit margin increased more than 600 basis points to 66% of total revenues compared with 60% for the same period in 2006. Fourth quarter 2007 net income was $5.3 million, or $0.41 per diluted share, compared with net income of $1.5 million, or $0.13 per diluted share, in the fourth quarter of 2006.

Non-GAAP net income, which excludes stock-based compensation expense and its related income tax effects, was $5.9 million, or $0.46 per diluted share, for the fourth quarter of 2007. This compares with non-GAAP net income of $2.5 million, or $0.21 per diluted share, in the fourth quarter of 2006, which excludes stock-based compensation expense and its related income tax effects. Please refer to the financial reconciliations included in this news release for a reconciliation of GAAP results to non-GAAP results for the three months ended December 31, 2007 and 2006.

"We concluded a banner year in 2007 with another quarter of record financial results, powered by continued customer demand for our flagship aesthetic laser systems," said President and Chief Executive Officer Michael Davin. "Laser product revenue increased 50% in the fourth quarter from the same period in
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
2. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
3. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
4. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
5. Immtech Reports Fiscal Third Quarter 2008 Results
6. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
7. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
8. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
9. Bunge Reports Fourth Quarter Net Income of $245 Million
10. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
11. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., SANTACRUZ,Calif.,Nov.24/PRNewswire/--Twomorep...enation,sleadingonlinejobboardandcareerssiteforlif...iaUniversityarenowmembersofthejobboard,joining28ot...jobboard, www.biocareercenter.com ,isonlyforpost-g...ifesciencecareersitesontheInternet,BioCareerCenter...
(Date:11/24/2009)... Health care employment gr...s the only one to show consistent growth during th...ospitals remain in trouble, and health systems are...ersonnel, instead of just administrators. , ...alth care employment continued growing in October ...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBio...ration(SFDA)hasapprovedthe,investigationalnewdruga...ninnovativeinsulinformulationtotreatdiabetes.ThisI...inicalstudy. , Diabetesisadisordercharacteris...ationsofdiabetesoftenresultinseveremicro-and,macro...
(Date:11/24/2009)..., TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswi...lyCalottoCapitalInc.,aleadingproviderofadvancedlas...rtilityclinicmarkets,todayreportedoperationalandfi...009. , ,Q32009Highlights,-Revenuewas$1.46million...nwas66.3percentcomparedwith66.1percentinQ3,2008,-N...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7
...any health plans are moving to in-source Disease M... costs and improve member outcomes , , , ,...nagement Solution(IHMS) platform fully integrates ... , , , , , , Blue Cross Blue Shi...to improve care and manage members, healthcare mor...
...., Feb. 2 MannKind Corporation (Nasdaq: MNKD ),...izing treatments for diabetes and cancer, announce...otechnology Industry Organization BIO CEO & In...:15 PM (EST) at the Hilton Waldorf Astoria in New ... Company will host a breakfast meeting for invited...
...ruary 2 Axentis Pharma AG is to present its,recen...apeutic formulation,for treating chronic lung dise...rum in Zurich, Switzerland. This invited talk come...present its recent achievements at the Biotech,Sho...any,s ongoing success,story is a recent capital in...
Other Biology Technology:Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 2Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 3Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 4MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 3
(Date:11/24/2009)...ntarctica has long held secrets of the earth,s his... there has been very little information on the env...ce for millions of years. Now, a team of researche...n funded to the tune of $10 million dollars by the...e bottom of things literally. These scientists wi...
(Date:11/23/2009)... The community-associated strain of the deadly su... to most common antibioticsposes a far greater hea... way into hospitals, according to a study in the D..., The new threat is easily picked up in fitness ...increased the overall burden of MRSA within hospit...
(Date:11/23/2009)...Current research suggests that a common oral bacte...ed report by Nichols et al, "Unique Lipids from a ...R2 Ligands Capable of Enhancing Autoimmunity," app...ournal of Pathology . , Multiple sclerosis (MS),...in and spinal cord, affects nearly 1 in 700 people...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 1Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 2Abaxis Inc to Present at the ThinkEquity Sixth Annual Growth Conference 56737 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 2PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 3PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 4PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 5PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 6
...e and then presented with a chemoattractant signal... a polarized morphology and aggregate to form a mi...pmental program that culminates in the formation o...w this streaming response is coordinated at a sing... Journal of Cell Biology ( www.jcb.org ). , Bes...
... chest wall deformity known as pectus excavatum co...exercise, according to a study published December ...ed at 11 North American hospitals, involved teleph...he ages of 8 and 21 who had pectus excavatum surge...he results were dramatic. Patients reported greatl...
...ant that has a potent effect on gene activity, cou...n the December issue of BioScience . The chemical...d and textile preservative, and as a pesticide on ...ns. , Tributyltin affects sensitive receptors in ...at very low concentrationsa thousand times lower t...
Other Biology News:Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3Persistent pollutant may promote obesity 2
Mouse Anti-Guinea Pig T-Cells, Pan Monoclonal Antibody, FITC Conjugated from AbD Serotec
GIBCO MEM Vitamin Solution (100X) liquid from Invitrogen
Rabbit Anti-Human Cytochrome P450 1A1 / 1A2 Polyclonal Antibody, Unconjugated from AbD Serotec
Sheep Anti-Human ESTRONE Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: